FDA approves capivasertib with fulvestrant for breast cancer. Nierengarten MB. Cancer 2024;130:835-836.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nierengarten MB. FDA approves capivasertib with fulvestrant for breast cancer. Cancer 2024;130:835-836.
PMID: 38396318